title: PPAR-α targeting in kidney fibrosis: is BAY PP1 just another renoprotector?
abstract: Interstitial fibrosis plays a major role in the progression of renal diseases. Peroxisome proliferator-activated receptor-α (PPAR-α) ligands are increasingly explored for their potential to reverse or halt tubulointerstitial fibrosis. This Commentary discusses new findings by Boor et al., who show that BAY PP1, a novel PPAR-α agonist, ameliorates renal fibrosis and dysfunction.
authors.affiliation: Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan. wbjeirami@khcc.jo
authors.forename: Wafa M
authors.initials: WM
authors.lastname: Elbjeirami
mesh_terms: D015097:3-Mercaptopropionic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D005355:Fibrosis / Q000517:prevention & control*; D007674:Kidney Diseases / Q000188:drug therapy*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: C572615:2-((4-(((2-methoxyethyl)(6-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)methyl)phenyl)sulfanyl)-2-methylpropanoic acid; D047492:Peroxisome Proliferator-Activated Receptors; D011743:Pyrimidines; D015097:3-Mercaptopropionic Acid